----

----

|   | Nevada                                                         |   | 36-3207413             |   |
|--------|----------------------------------------------------------------|--------|------------------------|--------|
|   | (State or other jurisdiction of incorporation or organization) |   | (IRS Employer Id. No.) |   |

| Large accelerated filer o Non-accelerated filer o |   | Accelerated filer o Smaller reporting company x |   |
|--------------------------------------------------------|--------|------------------------------------------------------|--------|

            

----

| PART I  FINANCIAL INFORMATION |                                                                                                                        | Page   |      |
|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|--------|-----------|
| Item 1.                                 | Financial Statements                                                                                                        |   |      |   |
|                                    | Condensed Consolidated Balance Sheets as of September 30, 2009 (unaudited) and December 31, 2008                            |   |      | 1 |   |
|                                    | Condensed Consolidated Statements of Operations (unaudited) for the three and nine months ended September 30, 2009 and 2008 |   |      | 2 |   |
|                                    | Condensed Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2009 and 2008           |   |      |  3 |   |
|                                    | Notes to Consolidated Financial Statements (unaudited)                                                                      |   |      | 4 |   |
| Item 2.                                 | Management’s Discussion and Analysis of Financial Condition and Results of Operations                                 |   |      |   14 |   |
| Item 3.                                 | Quantitative and Qualitative Disclosures About Market Risk                                                                  |   |      |   21 |   |
| Item 4T.                                | Controls and Procedures                                                                                                     |   |      |   22 |   |
| PART II OTHER INFORMATION               |                                                                                                                        |
| Item 1.                                 | Legal Proceedings                                                                                                           |   |      | 23 |   |
| Item 1A.                                | Risk Factors                                                                                                                |   |      |   23 |   |
| Item 2.                                 | Unregistered Sales of Securities and Use of Proceeds                                                                        |   |      |   23 |   |
| Item 3.                                 | Defaults Upon Senior Securities                                                                                             |   |      |   23 |   |
| Item 4.                                 | Submission of Matters to a Vote of Security Holders                                                                         |   |      |   23 |   |
| Item 5.                                 | Other Information                                                                                                           |   |      |   24 |   |
| Item 6.                                 | Exhibits                                                                                                                    |   |      |   24 |   |
| SIGNATURES                              |                                                                                                                        |   |   25 |   |

----

| Part I. | Financial Information |
|---------|-----------------------|

| Item 1 | Financial Statements |
|--------|----------------------|

| PHARMOS CORPORATION                                                                        |   |              |         |              |   |
|--------------------------------------------------------------------------------------------|--------|-------------------|--------------|-------------------|--------|
| Condensed Consolidated Balance Sheets                                                      |   |              |         |              |   |
|                                                                                       |   | September 30,2009 |         | December 31, 2008 |   |
| Assets                                                                                     |   | (Unaudited)       |         |              |   |
| Cash and cash equivalents                                                                  |   | $                 | 1,276,793    |              | $      | 4,730,282 |   |
| Restricted cash                                                                            |   |              | 38,998       |              |   | 38,998 |   |
| Prepaid expenses and other current assets                                                  |   |              | 62,362       |              |   | 1,049,898 |   |
| Total current assets                                                                       |   |              | 1,378,153    |              |   | 5,819,178 |   |
|                                                                                       |   |              |         |              |   |   |   |
| Fixed assets, net                                                                          |   |              | 3,409        |              |   | 9,692 |   |
| Other assets                                                                               |   |              | 36,278       |              |   | 143,294 |   |
|                                                                                       |   |              |         |              |   |   |   |
| Total assets                                                                               |   | $                 | 1,417,840    |              | $      | 5,972,164 |   |
|                                                                                       |   |              |         |              |   |   |   |
| Liabilities and Shareholders’ Equity                                                 |   |              |         |              |   |   |   |
| Accounts payable                                                                           |   | $                 | 200,469      |              | $      | 883,966 |   |
| Accrued expenses                                                                           |   |              | 219,717      |              |   | 615,663 |   |
| Accrued wages and other compensation                                                       |   |              | 54,000       |              |   | 87,000 |   |
| Total current liabilities                                                                  |   |              | 474,186      |              |   | 1,586,629 |   |
|                                                                                       |   |              |         |              |   |   |   |
| Other liabilities                                                                          |   |              | 11,103       |              |   | 44,316 |   |
| Milestone payable                                                                          |   |              | 1,000,000    |              |   | - |   |
| Convertible debentures                                                                     |   |              | 1,000,000    |              |   | 4,000,000 |   |
| Total liabilities                                                                          |   |              | 2,485,289    |              |   | 5,630,945 |   |
|                                                                                       |   |              |         |              |   |   |   |
|                                                                                       |   |              |         |              |   |   |   |
| Shareholders’ Equity                                                                 |   |              |         |              |   |   |   |
| Preferred stock, $.03 par value, 1,250,000 shares authorized, none issued and outstanding  |   |              |  -      |              |   | -  |   |
|     Common stock, $.03 par value; 120,000,000 and 60,000,000 shares    |   |              |         |              |   |   |   |
|     authorized, 57,291,155 and 26,210,290 issued and outstanding as of |   |              |         |              |   |   |   |
|     September 30, 2009 and December 31, 2008, respectively             |   |              | 1,718,735    |              |   | 786,307 |   |
| Stock subscription                                                                         |   |              | 180,000      |              |   | - |   |
| Paid-in capital in excess of par                                                           |   |              | 211,134,259  |              |   | 206,309,096 |   |
| Accumulated deficit                                                                        |   |              | (214,100,017 | )                 |   | (206,753,758 | ) |
| Treasury stock, at cost, 2,838 shares                                                      |   |              | (426         | )                 |   | (426 | ) |
| Total shareholders' (deficit) equity                                                       |   |              | (1,067,449   | )                 |   | 341,219 |   |
|                                                                                       |   |              |         |              |   |   |   |
| Total liabilities and shareholders' equity                                                 |   | $                 | 1,417,840    |              | $      | 5,972,164 |   |

| The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements. |
|---------------------------------------------------------------------------------------------------------------------|

----

| PHARMOS CORPORATION(Unaudited)Condensed Consolidated Statements of Operations |
|-------------------------------------------------------------------------------|
|                                                                          |   | Three months endedSeptember 30, |   | Nine months endedSeptember 30, |
|                                                                          |   |   |

|                                                     |   | 2009   |       |   | 2008   |   |       | 2009   |   |   | 2008       |   |
|----------------------------------------------------------|--------|--------|------------|--------|--------|--------|------------|--------|--------|--------|------------|--------|
| Expenses                                                 |   |   |       |   |   |   |       |   |   |   |       |   |
| Research and development                                 |   | $      | 1,047,260  |   |   | $      | 2,298,882  |   |   | $      | 4,266,337  |   |   | $ | 7,206,909 |   |
| In–process research and development Vela milestone |   |   | -          |   |   |   | -          |   |   |   | 1,180,000  |   |   |   | - |   |
| General and administrative                               |   |   | 342,320    |   |   |   | 436,758    |   |   |   | 1,101,865  |   |   |   | 1,687,747 |   |
| Depreciation and amortization                            |   |   | 2,030      |   |   |   | 24,853     |   |   |   | 6,283      |   |   |   | 89,514 |   |
| Total operating expenses                                 |   |   | 1,391,610  |   |   |   | 2,760,493  |   |   |   | 6,554,485  |   |   |   | 8,984,170 |   |
|                                                     |   |   |       |   |   |   |       |   |   |   |       |   |   |   |   |   |
| Loss from operations                                     |   |   | (1,391,610 | )      |   |   | (2,760,493 | )      |   |   | (6,554,485 | )      |   |   | (8,984,170 | ) |
|                                                     |   |   |       |   |   |   |       |   |   |   |       |   |   |   |   |   |
| Other (expense) income                                   |   |   |       |   |   |   |       |   |   |   |       |   |   |   |   |   |
| Debt conversion expense                                  |   |   | -          |   |   |   | -          |   |   |   | (596,104   | )      |   |   | - |   |
| Interest income                                          |   |   | 776        |   |   |   | 43,061     |   |   |   | 8,149      |   |   |   | 238,152 |   |
| Interest expense                                         |   |   | (29,607    | )      |   |   | (122,580   | )      |   |   | (196,537   | )      |   |   | (369,294 | ) |
| Other income (expense)                                   |   |   | 3,134      |   |   |   | (4,340     | )      |   |   | (7,282     | )      |   |   | 8,519 |   |
| Other expense, net                                       |   |   | (25,697    | )      |   |   | (83,859    | )      |   |   | (791,774   | )      |   |   | (122,623 | ) |
|                                                     |   |   |       |   |   |   |       |   |   |   |       |   |   |   |   |   |
| Net loss                                                 |   | $      | (1,417,307 | )      |   | $      | (2,844,352 | )      |   | $      | (7,346,259 | )      |   | $ | (9,106,793 | ) |
|                                                     |   |   |       |   |   |   |       |   |   |   |       |   |   |   |   |   |
| Net loss per share                                       |   |   |       |   |   |   |       |   |   |   |       |   |   |   |   |   |
| - basic and diluted                                      |   | $      | (0.02      | )      |   | $      | (0.11      | )      |   | $      | (0.16      | )      |   | $ | (0.35 | ) |
|                                                     |   |   |       |   |   |   |       |   |   |   |       |   |   |   |   |   |
| Weighted average shares outstanding                      |   |   |       |   |   |   |       |   |   |   |       |   |   |   |   |   |
| - basic and diluted                                      |   |   | 57,264,340 |   |   |   | 26,023,311 |   |   |   | 44,724,194 |   |   |   | 25,842,264 |   |

----

Condensed 

|                                                                                                  | Nine months endedSeptember 30, |   |
|-------------------------------------------------------------------------------------------------------|--------------------------------|--------|
|                                                                                                  | 2009                           |   |   | 2008 |   |
| Cash flows from operating activities                                                                  |                           |   |   |   |   |
| Net loss                                                                                              |                           |   | $ | (7,346,259 | ) |   | $ | (9,106,793 | ) |
|                                                                                                  |                           |   |   |   |   |   |   |   |   |
|  Adjustments to reconcile net loss to net cash used in operating activities:                     |                           |   |   |   |   |   |   |   |   |
| Depreciation and amortization                                                                         |                           |   |   | 6,283 |   |   |   | 89,514 |   |
| Amortization of deferred financing fees                                                               |                           |   |   | 28,633 |   |   |   | - |   |
| Provision for severance pay                                                                           |                           |   |   | - |   |   |   | (163,986 | ) |
| Stock based compensation                                                                              |                           |   |   | 128,021 |   |   |   | 278,224 |   |
| Debenture interest paid in common stock                                                               |                           |   |   | 130,403 |   |   |   | 159,602 |   |
| Milestone stock subscription                                                                          |                           |   |   | 180,000 |   |   |   | - |   |
| Debt conversion expense                                                                               |                           |   |   | 596,104 |   |   |   | - |   |
| Gain on disposition of fixed assets                                                                   |                           |   |   | - |   |   |   | (8,044 | ) |
| Changes in operating assets and liabilities:                                                          |                           |   |   |   |   |   |   |   |   |
| Research and development grants receivable                                                            |                           |   |   | - |   |   |   | 3,859 |   |
| Prepaid expenses and other current assets                                                             |                           |   |   | 880,522 |   |   |   | (331,715 | ) |
| Other assets                                                                                          |                           |   |   | 107,016 |   |   |   | (28,049 | )  |
| Accounts payable                                                                                      |                           |   |   | (683,497 | ) |   |   | 85,944 |   |
| Accrued expenses                                                                                      |                           |   |   | (194,279 | ) |   |   | 319,717 |   |
| Accrued wages and other compensation                                                                  |                           |   |   | (33,000 | ) |   |   | (562,590 | ) |
| Milestone payable                                                                                     |                           |   |   | 1,000,000 |   |   |   | - |   |
| Other liabilities                                                                                     |                           |   |   | (33,213 | ) |   |   | (33,216 | ) |
|                                                                                                  |                           |   |   |   |   |   |   |   |   |
| Net cash used in operating activities                                                                 |                           |   |   | (5,233,266 | ) |   |   | (9,297,533 | ) |
|                                                                                                  |                           |   |   |   |   |   |   |   |   |
| Cash flows from investing activities                                                                  |                           |   |   |   |   |   |   |   |   |
| Proceeds from disposition of fixed assets                                                             |                           |   |   | - |   |   |   | 115,238 |   |
| Proceeds from sale of short-term investments                                                          |                           |   |   | - |   |   |   | 3,686,568 |   |
| Severance pay funding                                                                                 |                           |   |   | - |   |   |   | 102,670 |   |
| Decrease in restricted cash                                                                           |                           |   |   | - |   |   |   | 47,303 |   |
|                                                                                                  |                           |   |   |   |   |   |   |   |   |
| Net cash provided by investing activities                                                             |                           |   |   | - |   |   |   | 3,951,779 |   |
|                                                                                                  |                           |   |   |   |   |   |   |   |   |
| Cash flows from financing activities                                                                  |                           |   |   |   |   |   |   |   |   |
| Proceeds from issuance of convertible debentures                                                      |                           |   |   | - |   |   |   | 4,000,000 |   |
| Proceeds from issuance of common stock and warrants, net of issuance costs                            |                           |   |   | 1,779,777 |   |   |   | - |   |
|                                                                                                  |                           |   |   |   |   |   |   |   |   |
| Net cash provided by financing activities                                                             |                           |   |   | 1,779,777 |   |   |   | 4,000,000 |   |
|                                                                                                  |                           |   |   |   |   |   |   |   |   |
| Net decrease in cash and cash equivalents                                                             |                           |   |   | (3,453,489 | ) |   |   | (1,345,754 | ) |
|                                                                                                  |                           |   |   |   |   |   |   |   |   |
| Cash and cash equivalents at beginning of year                                                        |                           |   |   | 4,730,282 |   |   |   | 7,481,741 |   |
|                                                                                                  |                           |   |   |   |   |   |   |   |   |
| Cash and cash equivalents at end of period                                                            |                           |   | $ | 1,276,793 |   |   | $ | 6,135,987 |   |
|                                                                                                  |                           |   |   |   |   |   |   |   |   |
|                                                                                                  |                           |   |   |   |   |   |   |   |   |
|                                                                                                  |                           |   |   |   |   |   |   |   |   |
| Supplementary information on operating and financing activity not involving cash flows:               |                           |   |   |   |   |   |   |   |   |
|                                                                                                  |                           |   |   |   |   |   |   |   |   |
|                                                                                                  |                           |   |   | 2009 |   |   |   | 2008 |   |
|                                                                                                  |                           |   |   |   |   |   |   |   |   |
|     Common shares issued for accrued interest as of December 2008                 |                           |   | $ | 201,667 |   |   | $ | - |   |
|     Write off of deferred financing fees associated with conversion of debentures |                           |   |   | 78,382 |   |   |   | - |   |
|     Conversion of debentures to common stock                                      |                           |   |   | 3,000,000 |   |   |   | - |   |
|                                                                                                  |                           |   |   |   |   |   |   |   |   |

----

Notes 

----

----

----

----

----

| Period Ended       |   | Grants Issued |   |      | Weighted Average Exercise Price |   |   | Weighted AverageFair Value |   |
|--------------------|--------|---------------|--------|-----------|---------------------------------|--------|--------|----------------------------|--------|
| September 30, 2009 |   |          |   | 1,050,000 |                            |   | $      | 0.22                       |   |   | $ | 0.17 |   |
| September 30, 2008 |   |          |   | 854,000   |                            |   | $      | 0.36                       |   |   | $ | 0.24 |   |

----

----

|   | · | $2 million + 2 million shares: NDA submission |
|--------|--------|-----------------------------------------------|

|   | · | $2 million cash +2.25 million shares: FDA approval |
|--------|--------|----------------------------------------------------|

|   | · | 1 million shares: Approval to market in Europe or Japan |
|--------|--------|---------------------------------------------------------|

|   | · | 4 million shares: $100 million sales of Dextofisopam, when and if approved, in any 12-month period |
|--------|--------|----------------------------------------------------------------------------------------------------|

|   | (1) | The last patient enrollment milestone and the successful phase 2b milestone have been amended and deferred as a condition of the convertible debentures issued January 3, 2008 (see Note 3 above). Payment of the cash component of these milestones, if achieved, will be deferred until such time as 1) the Company has successfully entered into a strategic collaboration or licensing agreement with a third party for thedevelopment of Dextofisopam resulting in an upfront cash fee of at least $10 million, and 2) payment of one or both of the cash milestones would still leave the Company with at least one year’s operating cash. If the foregoing conditions are not met, then the cash components of these milestones will not be paid. Additionally, the Vela acquisition agreement has been amended to defer the equity milestones issuable to the Vela shareholders related to such Phase 2b events until November 2, 2009 at the earliest. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|                                                               |   | September 30, |
|--------------------------------------------------------------------|--------|---------------|
|                                                               |   | 2009          |   | 2008 |
|                                                               |   |          |   |   |
| Stock options                                                      |   |          | 3,647,155 |   | 2,905,965 |
| Convertible debentures                                             |   |          | 1,428,571 |   | - |
| Vela milestone                                                     |   |          | 2,000,000 |   | - |
| Warrants                                                           |   |          | 18,000,000 |   | - |
|                                                               |   |          |   |   |   |
| Total potential dilutive securities not included in loss per share |   |          | 25,075,726 |   | 2,905,965 |

----

Geographic information for the three and nine months ending September 30, 2009 and 2008 are as follows: 

|                      |   | Three months ended September 30, |       |   | Nine months ended September 30, |   |
|---------------------------|--------|----------------------------------|------------|--------|---------------------------------|--------|
|                      |   | 2009                             |       |   | 2008                            |   |   | 2009 |   |   | 2008 |   |
| Net (loss) income         |   |                             |       |   |                            |   |   |   |   |   |   |   |
|   United States |   | $                                | (1,382,937 | )      |                            | $      | (2,836,178 | ) |   | $ | (7,253,924 | ) |   | $ | (9,093,340 | ) |
|   Israel        |   |                             | (34,370    | )      |                            |   | (8,174 | ) |   |   | (92,335 | ) |   |   | (13,453 | ) |
|                      |   | $                                | (1,417,307 | )      |                            | $      | (2,844,352 | ) |   | $ | (7,346,259 | ) |   | $ | (9,106,793 | ) |
|                      |   |                             |       |   |                            |   |   |   |   |   |   |   |   |   |   |   |
| Capital Expenditures      |   |                             |       |   |                            |   |   |   |   |   |   |   |   |   |   |   |
|   United States |   | $                                | -          |   |                            | $      | - |   |   | $ | - |   |   | $ | - |   |
|   Israel        |   |                             | -          |   |                            |   | - |   |   |   | - |   |   |   | - |   |
|                      |   | $                                | -          |   |                            | $      | - |   |   | $ | - |   |   | $ | - |   |

| Total Assets              |   | September 30, 2009 |      |   | December 31, 2008 |   |
|---------------------------|--------|--------------------|-----------|--------|-------------------|--------|
|   United States |   | $                  | 1,265,775 |   |              | $      | 5,417,338 |   |
|   Israel        |   |               | 152,065   |   |              |   | 554,826 |   |
|                      |   | $                  | 1,417,840 |   |              | $      | 5,972,164 |   |
|                      |   |               |      |   |              |   |   |   |
| Long Lived Assets, net    |   |               |      |   |              |   |   |   |
|   United States |   | $                  | 3,409     |   |              | $      | 9,692 |   |
|   Israel        |   |               | -         |   |              |   | - |   |
|                      |   | $                  | 3,409     |   |              | $      | 9,692 |   |

----

|   | Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations |
|--------|---------|---------------------------------------------------------------------------------------|

----

----

----

----

|                      |   | September 30, 2009 |      |   | December 31, 2008 |   |
|---------------------------|--------|--------------------|-----------|--------|-------------------|--------|
| Working capital           |   | $                  | 903,967   |   |              | $      | 4,232,549 |   |
|                      |   |               |      |   |              |   |   |   |
| Cash and cash equivalents |   | $                  | 1,276,793 |   |              | $      | 4,730,282 |   |
|                      |   |               |      |   |              |   |   |   |

----

----

|                           |   | Total  |      |   | Less than1 Year |   |    | 1 - 3Years |   |   | 3 - 5Years |   |   | Undetermined |       |
|--------------------------------|--------|--------|-----------|--------|-----------------|--------|---------|------------|--------|--------|------------|--------|--------|--------------|------------|
| Operating leases               |   | $      | 59,607    |   |            | $      | 59,607  |       |   | $      | -          |   |   | $            | -          |   |   | $ | - |   |
| Vela Milestone                 |   |   | 1,000,000 |   |            |   | -       |       |   |   | 1,000,000  |   |   |         | -          |   |   |   | - |   |
| Convertible debenture          |   |   | 1,000,000 |   |            |   | -       |       |   |   | -          |   |   |         | 1,000,000  |   |   |   | - |   |
| Convertible debenture interest |   |   | 308,333   |   |            |   | 100,000 |       |   |   | 200,000    |   |   |         | 8,333      |   |   |   | - |   |
| Total                          |   | $      | 2,367,940 |   |            | $      | 159,607 |       |   | $      | 1,200,000  |   |   | $            | 1,008,3333 |   |   | $ | - |   |

|   | · | $2 million + 2 million shares: NDA submission |
|--------|--------|-----------------------------------------------|

|   | · | $2 million cash +2.25 million shares: FDA approval |
|--------|--------|----------------------------------------------------|

|   | · | 1 million shares: Approval to market in Europe or Japan |
|--------|--------|---------------------------------------------------------|

|   | · | 4 million shares: $100 million sales of Dextofisopam, when and if approved, in any 12-month period |
|--------|--------|----------------------------------------------------------------------------------------------------|

----

Item 3

----

Item 4

----

Part II   Other Information

Item 1

Item 1A

Nasdaq Listing

Item 2

Item 3

Item 4

| Nominee                 |   | Votes for  |   | Votes withheld |
|-------------------------|--------|------------|--------|----------------|
| Srinivas Akkaraju       |   | 45,158,637 |   | 657,875        |
| Anthony B. Evnin        |   | 45,158,060 |   | 658,452        |
| Robert F. Johnston      |   | 45,160,133 |   | 656,379        |
| Charles W. Newhall, III |   | 45,111,636 |   | 704,876        |

----

Item 5

Item 6

| Number | Exhibit                                                                                                                                                                                                                           |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.1    | Restated Articles of Incorporation (Incorporated by reference to Appendix E to the Joint Proxy Statement/Prospectus included in the Form S-4 Registration Statement of the Company dated September 28, 1992 (No. 33-52398)        |
|   |                                                                                                                                                                                                                              |
| 3.2    | Certificate of Amendment of Restated Articles of Incorporation dated January 30, 1995 (Incorporated by reference to Annual Report on Form 10-K for the year ended December 31, 1994).                                             |
|   |                                                                                                                                                                                                                              |
| 3.3    | Certificate of Amendment of Restated Articles of Incorporation dated January 16, 1998 (Incorporated by reference to the Company’s Current Report on Form 8-K, dated February 6, 1998).                                      |
|   |                                                                                                                                                                                                                              |
| 3.4    | Certificate of Amendment of Restated Articles of Incorporation dated October 21, 1999 (Incorporated by reference to exhibit 4(e) to the Form S-3 Registration Statement of the Company filed September 28, 2000 (No. 333-46818)). |
|   |                                                                                                                                                                                                                              |
| 3.5    | Certificate of Amendment of Restated Articles of Incorporation dated July 19, 2002 (Incorporated by reference to Exhibit 3 to the Company’s Report on Form 10-Q for the quarter ended June 30, 2002).                       |
|   |                                                                                                                                                                                                                              |
| 3.6    | Certificate of Amendment of Restated Articles of Incorporation dated July 7, 2004 (Incorporated by reference to Exhibit 3.1 to the Company’s Report on Form 10-Q for the quarter ended June 30, 2004).                      |
|   |                                                                                                                                                                                                                              |
| 3.7    | Certificate of Amendment to Articles of Incorporation dated September 23, 2005 (Incorporated by reference to exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2005).          |
|   |                                                                                                                                                                                                                              |
| 3.8    | Certificate of Amendment to Articles of Incorporation dated August 5, 2009 (Incorporated by reference to exhibit 3.8 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2009).                   |
|   |                                                                                                                                                                                                                              |
| 4.1    | 2009 Incentive Compensation Plan (incorporated by reference to Appendix A to the Registrant’s Definitive Proxy Statement on Schedule 14A filed on June 18, 2009)                                                            |
|   |                                                                                                                                                                                                                              |
| 31.1   | Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15(d)-14(a), adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                                                         |
|   |                                                                                                                                                                                                                              |
| 31.2   | Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15(d)-14(a), adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                                                             |
|   |                                                                                                                                                                                                                              |
| 32.1   | Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                                                               |
|   |                                                                                                                                                                                                                              |
| 32.2   | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                                                                   |

----

SIGNATURE 

|                    |   | PHARMOS CORPORATION                                           |               |
|-------------------------|--------|---------------------------------------------------------------|--------------------|
|                    |   |                                                          |               |   |
|                    |   |                                                          |               |   |
| Date: November 12, 2009 |   |                                                          |               |   |
|                    |   | by:                                                           | /s/ S. Colin Neill |   |
|                    |   |                                                          |               |   |
|                    |   | S. Colin Neill                                                |               |
|                    |   | President, Chief Financial Officer, Secretary & Treasurer |               |
|                    |   | (Principal Accounting and Financial Officer)                  |               |

----